论文部分内容阅读
1989年10月～1991年12月,我们对62例晚期原发性肝癌进行了两种不同放疗方法的前瞻性随机临床研究。病人随机分为超分割每天2次放疗组(D_T5000～6000cGy/42～50次/4～5周)和全肝移动条放疗组。结果前组中位生存期5个月,后组2个月,差异有统计学意义;放疗后肿瘤缩小率前组为90.9％(30/33),后组为65.5％(19/29);疼痛缓解率两组分别为100％(33/33)和55.2％(16/29),差异有显著意义。结果表明,每天2次的超分割放疗具有延长生存时间,局部控制好,疗程短,放射反应轻等优点,对不能手术的原发性肝癌是一种有效的局部治疗方法。
From October 1989 to December 1991, we conducted a prospective randomized clinical study of 62 patients with advanced primary liver cancer using two different radiotherapy methods. The patients were randomly divided into two groups: hyperfractionated radiation therapy group (D_T5000-6000cGy/42-50/4-5 weeks) and whole liver moving radiation therapy group. Results The median survival time was 5 months in the former group and 2 months in the latter group. The rate of tumor reduction after radiotherapy was 90.9% (30/33) in the former group and 65.5% (19/29) in the latter group. The pain relief rate was 100% (33/33) and 55.2% (16/29) in the two groups, respectively, and the difference was significant. The results showed that hyperfractionated radiotherapy twice a day has the advantages of prolonged survival time, good local control, short course of treatment, and low radiation response. It is an effective local treatment method for primary liver cancer that cannot be operated.